Patrick B. Bolton

Patrick B. Bolton

Auto-generated profile, based on publicly available information

Patrick B. Bolton

Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, AZ

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in American Journal of Infection Control
Verified
Journal Article
Closed access
BSBradford B. Smith
Bradford B. Smith
WBWendelyn Bosch
Wendelyn Bosch
JOJohn C. O'HOro
John C. O'HOro
MGMarlene E. Girardo
Marlene E. Girardo
PBPatrick B. Bolton
Patrick B. Bolton
DMDavid P. Martin
David P. Martin

12 April 2021 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
PDF file
MFMax Feng
Max Feng
VLVeronica F. Lao
Veronica F. Lao
GCGarret Choby
Garret Choby
PBPatrick B. Bolton
Patrick B. Bolton
MMMichael J Marino
Michael J Marino
PCPhilip G. Chen
Philip G. Chen
Objectives: Topical vasoconstrictors and intravenous tranexamic acid (IV TXA) are safe and efficacious to decrease bleeding and improve the surgical field during endoscopic sinus surgery (ESS). The purpose of this study was to investigate practice patterns, awareness of clinical evidence, and comfort levels among anesthesia providers regarding these hemostatic agents for ESS. Methods: A total of 767 attending anesthesiologists, residents, and certified registered nurse anesthetists (CRNAs) at 5 United States academic centers were invited to participate in a survey regarding their experience with IV TXA and 3 topical vasoconstrictor medications (oxymetazoline, epinephrine, and cocaine) during ESS. Results: 330 (47%) anesthesia providers responded to the electronic survey. 113 (97%) residents, 92 (83%) CRNAs, and 52 (68%) attendings managed 5 or fewer ESS cases per month. Two-thirds of providers had not reviewed efficacy or safety literature for these hemostatic agents. Oxymetazoline was perceived safest, followed by epinephrine, IV TXA, and cocaine. Respondents considered potential side effects over surgical field visibility when selecting agents. The majority of providers had no formal training on these agents for ESS, but indicated interest in educational opportunities. Conclusion: Many anesthesia providers are unfamiliar with safety and efficacy literature regarding agents used to improve hemostasis for ESS, highlighting a need for development of relevant educational resources. Rhinologic surgeons have an opportunity to communicate with anesthesia colleagues on the use of hemostatic agents to improve the surgical field during ESS.

15 November 2022 in Contemporary Neurosurgery
Verified
Journal Article
Closed access
MBMegan M. J. Bauman
Megan M. J. Bauman
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
ETEvelyn Bs Turcotte
Evelyn Bs Turcotte
DPDevi P. Patra
Devi P. Patra
ATAli Turkmani
Ali Turkmani
BBBernard R. Md Bendok
Bernard R. Md Bendok